Soluble TWEAK Plasma Levels as a Novel Biomarker of Endothelial Function in Patients with Chronic Kidney Disease | Zendy

Mahmut İlker Yılmaz | Zendy; Juan Jesús Carrero | Zendy; Alberto Ortíz | Zendy; José Luis Martı́n-Ventura | Zendy; Alper Sönmez | Zendy; Mutlu Sağlam | Zendy; Halıl Yaman | Zendy; Müjdat Yenicesu | Zendy; Jesúus Egido | Zendy; Luis Miguel BlancoColio | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Soluble TWEAK Plasma Levels as a Novel Biomarker of Endothelial Function in Patients with Chronic Kidney Disease

Author(s) -

Mahmut İlker Yılmaz,

Juan Jesús Carrero,

Alberto Ortíz,

José Luis Martı́n-Ventura,

Alper Sönmez,

Mutlu Sağlam,

Halıl Yaman,

Müjdat Yenicesu,

Jesúus Egido,

Luis Miguel BlancoColio

Publication year - 2009

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.02760409

Subject(s) - wakefulness , gabaergic , dopaminergic , midbrain , neuroscience , pons , dopamine , neuron , optogenetics , medicine , endocrinology , inhibitory postsynaptic potential , biology , central nervous system , electroencephalography

Recently, we showed that soluble TNF-like weak inducer of apoptosis (sTWEAK) plasma levels are diminished in hemodialysis patients and had additive effects with IL-6 on survival. Because sTWEAK plasma level has been associated with the presence of chronic kidney disease (CKD) and cardiovascular disease, we hypothesized that in patients with CKD, sTWEAK levels may relate to the increased prevalence of endothelial dysfunction that usually accompanies the decline of estimated GFR (eGFR).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research